Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.

Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis. Monoclon Antib Immunodiagn Immunother. 2020 Oct 01;: Authors: Katsevman GA, Mariscal G, Barrios C, Domenech-Fernández P, Ziembinski C, Bhatia S Abstract Different signaling pathways have been studied in ankylosing spondylitis. New treatment options such as secukinumab could have an important role inhibiting the release of proinflammatory cytokine IL-17. The aim of this study was to compare the efficacy and safety of secukinumab in ankylosing spondylitis. A systematic review was conducted using MEDLINE and EMBASE databases to identify randomized clinical trials (RCTs) that assess the role of secukinumab in ankylosing spondylitis. The variables were safety (total adverse events, serious adverse events, headache, nasopharyngitis, cough, deaths, discontinuation due to adverse events, candida, neutropenia, and diarrhea) and efficacy based on quality-of-life scores (ASAS 20, ASAS 40, ASAS 5/6, ASASPR). Three RCTs (770 patients) that compare secukinumab with placebo were included in the study. There were significant differences in the quality-of-life scores in favor of the secukinumab group (p 
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Related Links:

AbstractAs a very promising immunotherapy, PD-1/PD-L1 blockade has revolutionized the treatment of a variety of tumor types, resulting in significant clinical efficacy and lasting responses. However, these therapies do not work for a large proportion of patients initially, which is called primary resistance. And more frustrating is that most patients eventually develop acquired resistance after an initial response to PD-1/PD-L1 blockade. The mechanisms that lead to primary and acquired resistance to PD-1/PD-L1 inhibition have remained largely unclear. Recently, the gut microbiome has emerged as a potential regulator for PD...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Patients and healthcare providers should be aware of the potential risks associated with testing, with attention to ensuring proper technique, and be prepared to recognize and manage adverse events.PMID:34547903 | DOI:10.1177/19458924211046725
Source: American Journal of Rhinology and Allergy - Category: ENT & OMF Authors: Source Type: research
Exp Mol Med. 2021 Sep 21. doi: 10.1038/s12276-021-00670-3. Online ahead of print.ABSTRACTPD-L1 is abnormally regulated in many cancers and is critical for immune escape. Fully understanding the regulation of PD-L1 expression is vital for improving the clinical efficacy of relevant anticancer agents. TGF-β plays an important role in the low reactivity of PD-1/PD-L1 antibody immunotherapy. However, it is not very clear whether and how TGF-β affects PD-L1 expression. In the present study, we show that TGF-β upregulates the expression of the transcriptional coactivator MRTF-A in non-small-cell lung cancer cells,...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
I know there will be plenty of night shifts during residency, but I am wondering if after becoming an attending, I would have more flexibility about when I take shifts. I would be willing to work 6 or 7 days a week to avoid the night shift. I find that I don't do well after staying up all night or shifting my sleep schedule around too much (headaches, tiredness).
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Medical Students (MD) Source Type: forums
Source: Journal of Biomedical Nanotechnology - Category: Nanotechnology Authors: Tags: review-article Source Type: research
Recently, many discoveries have elucidated the cellular and molecular diversity in the leukemic microenvironment and improved our knowledge regarding their complex nature. This has allowed the development of new therapeutic strategies against leukemia. Advances in biotechnology and the current understanding of T cell-engineering have led to new approaches in this fight, thus improving cell-mediated immune response against cancer. However, most of the investigations focus only on conventional cytotoxic cells, while ignoring the potential of unconventional T cells that until now have been little studied. γδ T cel...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
maría Ernest Nadal Xavier Solé Recent technological advances and the application of high-throughput mutation and transcriptome analyses have improved our understanding of cancer diseases, including non-small cell lung cancer. For instance, genomic profiling has allowed the identification of mutational events which can be treated with specific agents. However, detection of DNA alterations does not fully recapitulate the complexity of the disease and it does not allow selection of patients that benefit from chemo- or immunotherapy. In this context, transcriptional profiling has emerged as a promising to...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionThe FADG signature we constructed could provide a sensitive prognostic model for patients with glioma and contribute to improve immunotherapy management guidelines.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionWe demonstrated that the level of CD4+ GzmB+ T cells located in the center of tumor could provide great prognostic value for pMMR CRC patients. And the application of neoadjuvant chemotherapy further improves the infiltration of CD4+ GzmB+ T cells in the central compartment. Further studies into the application of CD4+ GzmB+ T cells in tumor immunotherapy are needed.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Ankylosing Spondylitis | Candida | Clinical Trials | Common Cold | Cough | Databases & Libraries | Headache | Immunotherapy | Microbiology | Migraine | Study